Scarica l'app Stockscreener
34.18
1.98%
0.6576
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ALKS Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$33.52
Aprire:
$33.92
Volume 24 ore:
462.30K
Relative Volume:
0.20
Capitalizzazione di mercato:
$5.65B
Reddito:
$1.51B
Utile/perdita netta:
$333.35M
Rapporto P/E:
17.53
EPS:
1.95
Flusso di cassa netto:
$315.22M
1 W Prestazione:
+0.99%
1M Prestazione:
+19.99%
6M Prestazione:
+30.73%
1 anno Prestazione:
+9.39%
Intervallo 1D:
$33.55
$34.40
Intervallo di 1 settimana:
$32.49
$34.67
Portata 52W:
$25.16
$36.45
Alkermes Plc Stock (ALKS) Company Profile
Nome
Alkermes Plc
Settore
Telefono
00-353-1-772-8000
Indirizzo
CONNAUGHT HOUSE, DUBLIN 4
Confronta ALKS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ALKS
Alkermes Plc
|
34.20 | 5.53B | 1.51B | 333.35M | 315.22M | 1.95 |
|
ZTS
Zoetis Inc
|
122.95 | 55.07B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
16.73 | 53.42B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
10.31 | 46.40B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.62 | 37.32B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
UTHR
United Therapeutics Corp
|
471.19 | 20.53B | 3.08B | 1.24B | 1.07B | 25.61 |
Alkermes Plc Stock (ALKS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-11 | Iniziato | Truist | Buy |
| 2025-09-26 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-09-03 | Iniziato | Wells Fargo | Overweight |
| 2025-07-15 | Iniziato | Goldman | Buy |
| 2025-06-17 | Aggiornamento | UBS | Neutral → Buy |
| 2025-05-28 | Iniziato | Needham | Buy |
| 2025-03-13 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2025-03-04 | Aggiornamento | UBS | Sell → Neutral |
| 2025-02-11 | Iniziato | Deutsche Bank | Buy |
| 2024-11-05 | Aggiornamento | Stifel | Hold → Buy |
| 2024-06-17 | Iniziato | TD Cowen | Buy |
| 2024-03-19 | Iniziato | Robert W. Baird | Outperform |
| 2024-02-20 | Downgrade | UBS | Neutral → Sell |
| 2023-11-20 | Ripresa | JP Morgan | Neutral |
| 2023-10-24 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2023-10-17 | Iniziato | UBS | Neutral |
| 2022-11-03 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2022-10-14 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2022-08-16 | Iniziato | Piper Sandler | Neutral |
| 2022-04-22 | Ripresa | Goldman | Buy |
| 2022-04-20 | Iniziato | Goldman | Buy |
| 2022-01-27 | Aggiornamento | Cantor Fitzgerald | Hold → Overweight |
| 2021-12-01 | Iniziato | Citigroup | Neutral |
| 2021-10-07 | Aggiornamento | Jefferies | Hold → Buy |
| 2021-09-02 | Downgrade | BofA Securities | Neutral → Underperform |
| 2020-10-15 | Aggiornamento | Mizuho | Neutral → Buy |
| 2020-07-30 | Downgrade | Goldman | Neutral → Sell |
| 2020-02-14 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2020-02-14 | Reiterato | H.C. Wainwright | Neutral |
| 2020-02-14 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-02-06 | Iniziato | Mizuho | Neutral |
| 2020-01-31 | Aggiornamento | Wolfe Research | Underperform → Peer Perform |
| 2019-09-05 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2019-07-15 | Aggiornamento | Goldman | Sell → Neutral |
| 2019-05-31 | Iniziato | H.C. Wainwright | Neutral |
| 2019-05-01 | Downgrade | Citigroup | Buy → Neutral |
| 2018-12-19 | Downgrade | Goldman | Neutral → Sell |
| 2018-12-14 | Iniziato | Wolfe Research | Underperform |
| 2018-12-13 | Downgrade | Credit Suisse | Outperform → Underperform |
| 2018-11-05 | Iniziato | Piper Jaffray | Neutral |
| 2018-08-07 | Iniziato | Stifel | Hold |
| 2018-06-21 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2018-06-06 | Iniziato | B. Riley FBR, Inc. | Buy |
| 2018-05-16 | Aggiornamento | Citigroup | Neutral → Buy |
| 2018-05-11 | Iniziato | BofA/Merrill | Buy |
Mostra tutto
Alkermes Plc Borsa (ALKS) Ultime notizie
Alkermes stock price target raised to $47 from $46 at UBS on Avadel deal - Investing.com
Corvus Pharmaceuticals Stock Rallies 209% in a Month: Here's Why - Finviz
Why analysts are rating Alkermes (ALKS) a buy - MSN
Jim Cramer on Alkermes: "I Think It's a Hold, Maybe a Weak One" - Finviz
Jim Cramer on Alkermes: “I Think It’s a Hold, Maybe a Weak One” - Insider Monkey
Weekly Earnings: Is Alkermes plc benefiting from interest rate changesQuarterly Trade Report & Verified Entry Point Detection - baoquankhu1.vn
ImmunityBio Stock Soars on FDA Talks for Anktiva sBLA Resubmission - Finviz
NVO Expands Aspect Tie-Up to Advance Curative Diabetes Cell Therapies - Finviz
Campbell & CO Investment Adviser LLC Has $741,000 Position in Alkermes plc $ALKS - MarketBeat
Precision Trading with Alkermes Plc (ALKS) Risk Zones - Stock Traders Daily
Jim Cramer Says Sell Super Micro — Calls A European Chipmaker 'Cheap And Good' - Sahm
Avadel Sets Court Date for Alkermes Acquisition Scheme - TipRanks
Avadel (NASDAQ: AVDL) moves Alkermes acquisition forward with Irish court hearing date - Stock Titan
ImmunityBio Shares Surge on Updated Durable Lymphoma Study Results - Finviz
Alkermes (ALKS) Is Up 6.8% After FDA Breakthrough Tag for Narcolepsy Drug Candidate AlixorextonWhat's Changed - simplywall.st
Aug Outlook: Is Braemar Hotels Resorts Inc part of any ETF2025 Trading Recap & Fast Entry Momentum Trade Alerts - baoquankhu1.vn
Alkermes Receives FDA Breakthrough Therapy Designation for Alixorexton, Potentially Accelerating Development - Intellectia AI
Alkermes (ALKS) Is Up 6.6% After FDA Breakthrough Tag for Narcolepsy Drug Alixorexton - Yahoo Finance
Rate Cut: What analysts say about Alkermes plc stockTrade Performance Summary & High Accuracy Swing Trade Signals - baoquankhu1.vn
Aug Final Week: Is Alkermes plc benefiting from interest rate changesJobs Report & Short-Term High Return Ideas - baoquankhu1.vn
Recap Report: Can Alkermes plc stock outperform in a bear market - baoquankhu1.vn
Erasca Stock Surges 42% in a Week: Here's What You Should Know - Finviz
ALKS: RBC Capital Raises Price Target to $47, Maintains 'Outperf - GuruFocus
Piper Sandler Raises Price Target for ALKS to $45, Reiterates Ov - GuruFocus
Are Medical Stocks Lagging Alkermes (ALKS) This Year? - sharewise.com
Avadel Pharmaceuticals shareholders approve $2.37B takeover bid - The Business Journals
Apellis Stock Crashes 23% in a Week: Here's What You Should Know - Finviz
Alkermes PLC (ALKS) Stock Price Up 3.16% on Jan 15 - GuruFocus
Alkermes (NASDAQ:ALKS) Rating Increased to Strong-Buy at Zacks Research - MarketBeat
Alkermes plc (NASDAQ:ALKS) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Will Alkermes (ALKS) Beat Estimates Again in Its Next Earnings Report? - Finviz
Best Value Stocks to Buy for Jan.14 - The Globe and Mail
Update Report: Can inTEST Corporation scale operations efficientlySell Signal & Real-Time Chart Pattern Alerts - baoquankhu1.vn
Improved Earnings Required Before Alkermes Plc (NASDAQ:ALKS) Shares Find Their Feet - 富途牛牛
Aug Rallies: Will Alkermes plc stock remain a Wall Street favorite2025 Volume Leaders & Momentum Based Trading Ideas - Bộ Nội Vụ
Retail Trends: Can Alkermes plc stock deliver 10 annual returnsInsider Selling & Precise Trade Entry Recommendations - Bộ Nội Vụ
Avadel Shareholders Approve Acquisition by Alkermes - Sleep Review
Alkermes Touts $10B Sleep Market as ALKS 2680 Heads to Phase 3, Avidel Deal Nears Close - Yahoo Finance
ALKS: ALKS 2680 advances to Phase 3, targeting major sleep disorders and expanding commercial reach - TradingView — Track All Markets
ALKS: ALKS 2680 advances as a potential blockbuster, driving growth and sleep medicine expansion - TradingView — Track All Markets
Avadel shareholders approve acquisition by Alkermes - Investing.com Nigeria
Alkermes (ALKS) Secures Shareholder Approval for Avadel Acquisition - GuruFocus
Avadel shareholders approve acquisition by Alkermes By Investing.com - Investing.com South Africa
Avadel Shareholders Approve Acquisition by Alkermes plc - TipRanks
Avadel Pharmaceuticals Announces that Avadel Shareholders Approve the Proposed Acquisition by Alkermes - The Manila Times
Avadel Pharmaceuticals plc Approves Scheme of Arrangement for Alkermes Acquisition - Quiver Quantitative
Shareholders back Avadel sale to Alkermes after strong vote - Stock Titan
Alkermes plans Avadel acquisition to expand sleep portfolio - TipRanks
Alkermes plc (ALKS): Investor Outlook Reveals 47.29% Potential Upside Amid Robust Product Pipeline - DirectorsTalk Interviews
How to contact the Daily Bulletin - FinancialContent
Buybacks Report: What dividend safety score for Alkermes plc stock2025 Key Highlights & Smart Swing Trading Techniques - Bộ Nội Vụ
Alkermes Plc Azioni (ALKS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.57%
1.71%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):